Market capitalization | CHF1.01b |
Enterprise Value | CHF878.27m |
P/E (TTM) P/E ratio | 7.85 |
EV/FCF (TTM) EV/FCF | 5.98 |
EV/Sales (TTM) EV/Sales | 3.51 |
P/S ratio (TTM) P/S ratio | 4.04 |
P/B ratio (TTM) P/B ratio | 2.02 |
Dividend yield | 3.30% |
Last dividend (FY25) | CHF1.95 |
As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.
1 Analyst has issued a forecast COSMO Pharmaceuticals:
1 Analyst has issued a forecast COSMO Pharmaceuticals:
Dec '24 |
+/-
%
|
||
Revenue | 250 250 |
188%
188%
|
|
Gross Profit | 208 208 |
314%
314%
|
|
EBITDA | 151 151 |
7,272%
7,272%
|
EBIT (Operating Income) EBIT | 140 140 |
8,040%
8,040%
|
Net Profit | 125 125 |
1,336%
1,336%
|
In millions CHF.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
Head office | Netherlands |
CEO | Giovanni Napoli |
Employees | 322 |
Founded | 2016 |
Website | www.cosmopharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.